CHICAGO (Reuters) - A trial of Johnson & Johnson's prostate cancer pill, Zytiga, found that it slowed the spread of the disease by 58 percent in men who had stopped responding to hormonal drugs but not yet treated with chemotherapy, potentially offering new hope for patients who see their cancer return. (Source: Reuters: Health)MedWorm Sponsor Message: Have a look at The Psychology Daily, the new psychology portal powered by MedWorm, with all the latest psychology news and research updated daily.
Read from Source
|
